Published Analysis of Sotagliflozin (INPEFA(TM)) Clinical Data Demonstrates Significant Reductions in the Risk of Hospital Readmissions for Heart Failure

Post-Hoc Analysis of SOLOIST-WHF Clinical Data Published in Journal of the American College of Cardiology: Heart Failure

Risk Reductions of Approximately 50% Demonstrated for Heart Failure Readmissions and for Composite of CV Death and Heart Failure Readmissions at 30- and 90-Days Following Hospital Discharge

Read more at globenewswire.com